McEachern Jennifer A, Bingham John, Crameri Gary, Green Diane J, Hancock Tim J, Middleton Deborah, Feng Yan-Ru, Broder Christopher C, Wang Lin-Fa, Bossart Katharine N
CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia.
Vaccine. 2008 Jul 23;26(31):3842-52. doi: 10.1016/j.vaccine.2008.05.016. Epub 2008 Jun 2.
Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sG(HeV) were employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses.
尼帕病毒（NiV）和亨德拉病毒（HeV）是密切相关的致命人畜共患副粘病毒，在过去10年中不断出现和再次出现。在本研究中，一种仅含有来自HeV的重组、可溶性附着糖蛋白（sG(HeV)）和CpG佐剂的亚单位疫苗制剂，在猫模型中作为潜在的NiV疫苗进行了评估。使用了不同量的sG(HeV)，并检测了sG诱导的免疫反应。接种疫苗的动物全身表现出不同水平的NiV特异性Ig，重要的是，所有接种疫苗的猫在黏膜上都具有抗原特异性IgA。在用NiV（50,000TCID50）进行口鼻攻毒后，所有接种疫苗的动物都受到了疾病保护，尽管在攻毒后第21天在一只动物中检测到了病毒。在该动物模型中引发保护性全身和黏膜免疫的能力，为开发针对亨尼帕病毒的人亚单位疫苗取得了重大进展。
Zotero 插件
